STERIS plc (STE) fair value analysis

S&P 500 · Updated 2026-09-07

STERIS plc is a healthcare company that provides sterilization and contamination control products and services for hospitals, surgical centers, and pharmaceutical manufacturers. The company operates globally with a significant presence in North America, Europe, and other international markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, STE is trading at a 10–25% discount to estimated fair value.

STE currently ranks #33 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $224.59
Sector: Healthcare
12-month range: $211.07–$264.24

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Momentum grade: A
Leverage: Low
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Neutral
52-week position: The lower-middle quarter of its range
DCF cross-check: Overvalued

What our data shows for STE

Our model validated 17 trailing price-to-earnings windows for STE, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $211.07–$264.24.
The 14-day relative strength index sits at a neutral 37.
3 of the last 12 weekly snapshots showed positive price momentum.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for STE
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent STE news

TickrTrends' derived news-sentiment signal for STE is currently leaning positive, computed from recent coverage.

STERIS to Present at the Morgan Stanley Healthcare Conference (manilatimes.net, 2026-09-01)
TickrTrends take: STERIS is scheduled to present at the Morgan Stanley Healthcare Conference, an event that typically draws significant institutional investor attention to healthcare companies. For valuation-focused readers, such conference presentations offer an opportunity to assess management's strategic priorities and capital allocation plans, which can inform views on whether the current undervalued designation remains appropriate. The presentation may provide insight into the company's growth trajectory and operational efficiency initiatives that could justify or challenge TickrTrends' current assessment in the competitive Healthcare sector.
STERIS Stock Outlook: Is Wall Street Bullish or Bearish? (finance.yahoo.com, 2026-08-26)
TickrTrends take: STERIS operates in the Healthcare sector and is currently assessed as undervalued according to TickrTrends' derived valuation metrics. Given this undervalued status, investors focused on valuation fundamentals should monitor whether Wall Street's positioning on the stock reflects the same assessment or diverges from it. A disconnect between analyst sentiment and the current valuation standing could signal either an opportunity if bullish views support the undervalued thesis or a potential risk factor if bearish sentiment suggests deeper concerns about the company's prospects.
STERIS Announces Financial Results for Fiscal 2027 First Quarter (manilatimes.net, 2026-08-05)
TickrTrends take: STERIS reported financial results for its fiscal 2027 first quarter, providing updated operational and financial performance data for investors monitoring the company's fundamentals. Given TickrTrends' current assessment that STE is undervalued, valuation-focused readers should examine whether the quarter's results support stronger pricing relative to healthcare sector peers or validate the disconnect between the stock's current market value and its underlying business performance. Key metrics from this earnings report will be instrumental in determining whether the undervalued designation reflects genuine opportunity or changing business conditions that merit reassessment.

What people are saying

Follow the STE conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for STE show movement in relative sector positioning this week. The stock's sector discount rank improved from number 38 to number 33, indicating a narrowing of its valuation discount relative to other Healthcare sector peers. The current valuation verdict remains Undervalued.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is STE stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), STE is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is STE's TickrTrends verdict?

STE's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does STE compare to other Healthcare stocks?

STE ranks #33 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is STE overbought or oversold?

STE's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

STE vs AVAH · STE vs CI · STE vs GEHC · STE vs IDXX · STE vs INCY